Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...

One area that medical device manufacturers often overlook in post-market surveillance (PMS) planning for EU MDR and EU IVDR ...